Risk Factors Influencing Efficacy and Prognosis Evaluation of Neoadjuvant Systemic Therapy in Triple‐Positive Breast Cancer
Lin‐Rui Miao, Hao Liu, Hai‐Ying Yu, Jian Chen, Ming‐Yu Yang, Ya‐Lan Zhang, Gang Tu, Ling‐Feng Tang · 2026
Read Risk Factors Influencing Efficacy and Prognosis Evaluation of Neoadjuvant Systemic Therapy in Triple‐Positive Breast Cancer by Lin‐Rui Miao, Hao Liu, Hai‐Ying Yu, Jian Chen, Ming‐Yu Yang, Ya‐Lan Zhang, Gang Tu, Ling‐Feng Tang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13399811.txt.
Description
Lin-Rui Miao and colleagues hunt for what predicts response to drug therapy before surgery in a triple-marked breast cancer, in this study from twenty twenty-six. Triple-positive tumors carry three targets at once: two hormone receptors and HER2. The team reviewed 520 patients with HER2-positive cancer treated at one Chongqing hospital over six years.
The triple-positive group cleared all visible cancer by surgery far less often than the hormone-negative group: about 30 percent against 50. Yet long-term survival did not differ between the groups. Within the triple-positive group, full clearance did predict longer freedom from disease. Three factors predicted clearance: the drug regimen, the estrogen receptor level, and a growth index called Ki67. The team folded them into a scoring chart, a nomogram, and checked it on a later group of 143 patients, where it held up well. They offer it for early, tailored treatment planning.
Catalog record
| CREATOR | Lin‐Rui Miao, Hao Liu, Hai‐Ying Yu, Jian Chen, Ming‐Yu Yang, Ya‐Lan Zhang, Gang Tu, Ling‐Feng Tang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |